Filippo Pietrantonio
YOU?
Author Swipe
View article: Efficacy and Safety of Anti–PD-(L)1 Treatments: A Systematic Review and Meta-Analysis of Asian vs Non-Asian Patients With Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Anti–PD-(L)1 Treatments: A Systematic Review and Meta-Analysis of Asian vs Non-Asian Patients With Esophageal Squamous Cell Carcinoma Open
View article: Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials Open
PURPOSE Human epidermal growth factor receptor 2 (HER2) amplification/overexpression (HER2-pos) is detected in 5% of RAS/BRAF wild-type metastatic colorectal cancers (mCRCs). Its prognostic/predictive role in terms of benefit from anti-EGF…
View article: Reply letter to comments on: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial
Reply letter to comments on: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial Open
View article: Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials Open
Tumor sidedness and hyperselection status significantly influence maintenance strategy efficacy in mCRC. For left-sided, negative hyperselected patients, Panitumumab monotherapy may optimize efficacy while minimizing toxicity. Further inve…
View article: Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study
Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study Open
Background & Aims Cholangiocarcinoma (CCA) is a rare cancer with limited therapeutic options and a poor prognosis. While first‐line combination therapies have improved outcomes, second‐line treatment remains challenging. Ivosidenib, an IDH…
View article: First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer Open
Background Patients with deficient mismatch repair (dMMR) and/or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) show marked sensitivity to immune checkpoint inhibitors (ICIs). Dual PD-1/CTLA-4 blockade with niv…
View article: Figure S5 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Figure S5 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer Open
Evaluation of the expression of EGFR and HER2 in cetuximab sensitive vs resistant cells.
View article: Figure S9 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Figure S9 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer Open
Overall survival according AREG or EREG overexpression in ACRG cohort.
View article: Figure S1 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Figure S1 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer Open
Features of the analyzed models.
View article: Data from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Data from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer Open
EGFR is a potential therapeutic target in gastroesophageal cancer. However, negative results from several phase II/III clinical trials have hindered the approval of EGFR inhibitors for treating gastroesophageal adenocarcinoma. Preclinical …
View article: Figure S8 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Figure S8 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer Open
Overall survival according HER3 expression in the COG cohort.
View article: Figure S3 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Figure S3 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer Open
Evaluation of apoptosis and cell cycle upon cetuximab treatment.
View article: Figure S6 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Figure S6 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer Open
AREG and EREG RNAscope staining and quantification.
View article: Figure S2 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Figure S2 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer Open
Cross‐sensitivity of GEA primary cells among EGFR targeting drugs.
View article: Figure S10 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Figure S10 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer Open
Evaluation of EGFR pathway activation.
View article: Figure S7 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Figure S7 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer Open
H‐score correlation between the pathologists for AREG, EREG, and HER3 biomarkers.
View article: AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer Open
EGFR is a potential therapeutic target in gastroesophageal cancer. However, negative results from several phase II/III clinical trials have hindered the approval of EGFR inhibitors for treating gastroesophageal adenocarcinoma. Preclinical …
View article: 6MO Rechallenge with amivantamab, an EGFR-MET bispecific antibody, after disease progression on prior EGFR inhibitor in left-sided RAS/BRAF wild-type metastatic colorectal cancer: Updated results from OrigAMI-1
6MO Rechallenge with amivantamab, an EGFR-MET bispecific antibody, after disease progression on prior EGFR inhibitor in left-sided RAS/BRAF wild-type metastatic colorectal cancer: Updated results from OrigAMI-1 Open
View article: Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial Open
View article: Supplementary Figure 4 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Figure 4 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis Open
Supplementary Figure 4. Clustering parameters and immune cell subtypes across clusters.
View article: Supplementary Table 2 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 2 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis Open
Supplementary Table 2. Gene signatures, target genes, and whole transcriptome derivatives.
View article: Supplementary Figure 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Figure 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis Open
Supplementary Figure 1. Quality control parameters for WES data utilized in the study.
View article: Supplementary Figure 2 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Figure 2 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis Open
Supplementary Figure 2. Niche remodelling and prognostic significance of SERPINE1.
View article: Supplementary Table 6 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 6 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis Open
Supplementary Table 6. A5 in mouse models.
View article: Supplementary Table 4 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 4 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis Open
Supplementary Table 4. Comparisons of histological features between SC1 and SC2.
View article: Supplementary Table 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis Open
Supplementary Table 1. Cohort and sample overview.
View article: Supplementary Table 5 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 5 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis Open
Supplementary Table 5. T-test comparisons between DSP ROIs and top 20 (10 up and 10 down) discriminatory genes.
View article: Supplementary Figure 5 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Figure 5 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis Open
Supplementary Figure 5. Overall survival KM curve of patients stratified by SC2 signature (Q1 vs Q4) of peritoneal samples only.
View article: Supplementary Table 3 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 3 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis Open
Supplementary Table 3. Spatial QC metrics and cell type markers.
View article: Supplementary Methods 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Methods 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis Open
Supplementary Methods 1. Supplementary Methods, DNA extraction and whole exome sequencing, Mutation calling and mutational signatures, Whole transcriptome sequencing, Spatial profiling, Methods of A5 Discovery and Validation, Other statist…